Health Day - ONLINE EDITION
Posted: 10/8/2013 5:00 PM | Comments: 0
TUESDAY, Oct. 8 (HealthDay News) -- Treating pancreatic cancer patients with the chemotherapy drug gemcitabine (Gemzar) after surgery improved survival rates when compared to doing nothing, German researchers report.
However, one expert noted that the finding may not be clinically relevant anymore.
The trial showed the benefit of treatment over no treatment, said Dr. Nilofer Azad, director of the Phase 1 Clinical Trials Group at Johns Hopkins Kimmel Cancer Center in Baltimore. "But more recently, the question has turned to what should that treatment be, not whether there should be a treatment," Azad noted.
Today, no patients would be randomized to no therapy, she added. "There are other drug combinations that we are looking at now. There are other novel treatments and experimental therapies we are looking at. Those are the open questions," Azad said.
For example, the findings of a Japanese study published in the April 1 issue of the Journal of Clinical Oncology showed that an experimental drug plus gemcitabine improved survival longer than either drug alone, she noted.
Despite these advances, the overall picture for pancreatic cancer remains bleak, Azad added.
"It's still depressing. Pancreatic cancer still has the worst cure rate of any solid tumor. It's the fifth-leading killer even though it's rarer than common cancers, and we haven't made a substantial impact on it," she said.
What is really needed is a way to diagnose pancreatic cancer early, when it is still curable. "The best way we can lower the death rate from pancreatic cancer is to diagnose it when it is very early on," Azad stressed.
The latest report was published in the Oct. 9 issue of the Journal of the American Medical Association.
For the study, a team led by Dr. Helmut Oettle, of the Charite-Universitatsmedizin in Berlin, gathered data on 354 patients with pancreatic cancer who had their tumor removed. These patients were randomly assigned to six months of treatment with gemcitabine or observation alone.
The patients began the study between July 1998 and December 2004, and were followed until September 2012.
By September 2012, 308 patients (87 percent) had relapsed. The average disease-free survival was 13.4 months among patients who received gemcitabine, compared with 6.7 months among those who received no treatment, the researchers found.
At the end of the study, 316 patients (nearly 90 percent) had died and 38 patients were still alive. Of those still living, 23 had been treated with gemcitabine while 15 hadn't, the study authors noted.
Oettle's group found a statistically significant difference in overall survival between the groups, with an average of 22.8 months for those taking gemcitabine, compared with 20.2 months for those in the observation-only group.
Among patients who received gemcitabine there was also a statistically significant absolute 10.3 percent improvement in five-year survival, compared with those who received no treatment (20.7 percent versus 10.4 percent) and a 4.5 percent improvement in the 10-year survival (12.2 percent versus 7.7 percent), the researchers found.
For more on pancreatic cancer, visit the U.S. National Cancer Institute.
Have you found an error, or know of something we’ve missed in one of our stories? Please use the form below and let us know.
Having problems with the form?Contact Us Directly
Doctor helping to develop surgery black box
Drug Gives 'New Hope' Against Heart Failure, Expert Says
Get your butt in gear: Strong glutes mean healthy back, hip and knees
Training basket: Chantal Larocque
Health region faxes patients' reports to wrong place
Spaceflight Might Weaken Astronauts' Immune Systems
Take Steps to Control Bunions
Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans
Faced With Prostate Cancer, It Helps to Know the Enemy
Winnipeg lab created, tested Ebola drug ZMapp
Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says
Scientists Find Differences in Brains of Those With Dyslexia
Encouraging Your Baby's Babbling May Speed Language Development
Study Counters Critics of Plainer Cigarette Packaging
European MRSA Originated in Sub-Saharan Africa, Study Finds
'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds
Health Highlights: Aug. 29, 2014
Health Tip: Exercise While Watching Television
Health Tip: Teach Your Child to Read Food Labels
OK, so we have germs. But they're our unique germs
Life of a pot-store owner: Guards and cash
Take the time to pack kids a healthier lunch
L'Alpette brand sheep cheese recalled
Could Too Much Salt Harm MS Patients?
Saskatchewan to cover cystic fibrosis drug
Parents' Fights May Strain Bonds With Their Kids
Most U.S. Babies Get Their Vaccines: CDC
Less Sleep in Teen Years Tied to More Pounds at 21
Shades of Pigpen: We travel with our own germs
Scientists dig into Ebola's deadly DNA for clues
Electrical Pulses to Scalp May Boost Memory: Study
Gene Research Yields Insights Into Ebola Virus
Your Family's Germs May Move With You
Donated Livers Not Harmed by Travel Distances, Study Finds
Ebola Outbreak Could Infect 20,000 People, U.N. Says
Young Driver's Gender May Play Role in Timing, Type of Crash
Health Highlights: Aug. 28, 2014
US to begin safety testing Ebola vaccine next week
Concussion Recovery Can Reverse After Return to Activity, Study Shows
Eye Pigment May Help Vision in Hazy Conditions